Zura BioZURA
ZURA
About: Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.
Employees: 30
0
Funds holding %
of 7,311 funds
–
Analysts bullish %
Fund manager confidence
Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)
20% more repeat investments, than reductions
Existing positions increased: 24 | Existing positions reduced: 20
1.18% more ownership
Funds ownership: 65.69% [Q4 2024] → 66.87% (+1.18%) [Q1 2025]
0% more funds holding in top 10
Funds holding in top 10: 1 [Q4 2024] → 1 (+0) [Q1 2025]
14% less funds holding
Funds holding: 87 [Q4 2024] → 75 (-12) [Q1 2025]
45% less capital invested
Capital invested by funds: $107M [Q4 2024] → $59M (-$48.3M) [Q1 2025]
58% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 19
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $15K
Research analyst outlook
1 Wall Street Analyst provided 1 year price targets over the past 3 months
Low target
$17
1,445%
upside
Avg. target
$17
1,445%
upside
High target
$17
1,445%
upside
1 analyst rating
1 positive
100%
0 neutral
0%
0 negative
0%
Oppenheimer Jeff Jones | 1,445%upside $17 | Outperform Maintained | 9 May 2025 |
Financial journalist opinion
Neutral
Business Wire
6 days ago
Zura Bio Announces Chief Financial Officer Transition
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced the appointment of Eric Hyllengren as Chief Financial Officer, effective July 7, 2025. He will succeed Verender Badial, who will step down from the role and remain with the company as a non-executive employee through July 31, 2025, to support a seamless transi.
Neutral
Business Wire
1 month ago
Zura Bio to Present at the Jefferies Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today announced that members of its senior leadership team will present a corporate overview at the Jefferies Global Healthcare Conference on Wednesday, June 4, 2025, at 3:10 PM ET in New York, NY. In addition, the Company will participate in one-on-one meeti.
Neutral
Business Wire
1 month ago
Zura Bio Launches Global Phase 2 TibuSHIELD Study to Evaluate Tibulizumab in Adults with Hidradenitis Suppurativa
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSHIELD, a Phase 2 study evaluating tibulizumab in adults with hidradenitis suppurativa.
Neutral
Business Wire
1 month ago
Zura Bio Reports First Quarter 2025 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for a range of autoimmune and inflammatory diseases, today reported financial results for the first quarter ended March 31, 2025, and provided recent corporate updates. “The first quarter of 2025 reflected steady progress across our clinical and operational priorities,” said Robert Lisicki, Chief Executive Offi.
Neutral
Business Wire
3 months ago
Zura Bio Reports Full Year 2024 Financial Results and Recent Corporate Updates
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio” or the “Company”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today reported full year 2024 financial results and recent corporate updates. “In 2024, we reached key milestones that reinforced our financial foundation, expanded our leadership team, and advanced our clinical pipeline, highlighting our commitment to establishing a le.
Neutral
Business Wire
4 months ago
Zura Bio to Present at the Leerink Partners Global Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Leerink Partners Global Healthcare Conference on Tuesday, March 11, 2025, at 1:40 p.m. ET, and will host investor meetings in Miami, FL. A live webcast and a replay of the presentation.
Positive
Zacks Investment Research
5 months ago
Down -35.58% in 4 Weeks, Here's Why You Should You Buy the Dip in Zura Bio Limited (ZURA)
Zura Bio Limited (ZURA) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Neutral
Business Wire
6 months ago
Zura Bio Launches Global Phase 2 TibuSURE Study to Evaluate Tibulizumab in Adults With Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio launches TibuSURE, a Phase 2 global study evaluating tibulizumab for the treatment of systemic sclerosis (SSc) in adults.
Neutral
Business Wire
7 months ago
Zura Bio to Present at the Piper Sandler 36th Annual Healthcare Conference
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced that members of its senior leadership team will participate in a fireside chat at the Piper Sandler 36th Annual Healthcare Conference on Tuesday, December 3, 2024, at 9:00 a.m. ET, and will host investor meetings in New York, NY. A live webcast and a replay of the presen.
Neutral
Business Wire
7 months ago
Zura Bio Announces Submission of Protocol to U.S. Food and Drug Administration for the Phase 2 Study of Tibulizumab in Adults with Systemic Sclerosis
HENDERSON, Nev.--(BUSINESS WIRE)---- $ZURA #TeamZura--Zura Bio Limited (Nasdaq: ZURA) (“Zura Bio”), a clinical stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases, today announced the submission of a protocol to its open Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA) for a Phase 2 study evaluating tibulizumab, a humanized tetravalent bispecific dual antagonist antibody designed to neutralize both IL-17A.
Charts implemented using Lightweight Charts™